TWI583383B - 治療高血壓之醫藥組成物及方法 - Google Patents

治療高血壓之醫藥組成物及方法 Download PDF

Info

Publication number
TWI583383B
TWI583383B TW100115056A TW100115056A TWI583383B TW I583383 B TWI583383 B TW I583383B TW 100115056 A TW100115056 A TW 100115056A TW 100115056 A TW100115056 A TW 100115056A TW I583383 B TWI583383 B TW I583383B
Authority
TW
Taiwan
Prior art keywords
amlodipine
pharmaceutical composition
dextromethorphan
hypertension
blood pressure
Prior art date
Application number
TW100115056A
Other languages
English (en)
Chinese (zh)
Other versions
TW201206437A (en
Inventor
陳肇文
王錫傑
莊欣怡
Original Assignee
東生華製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東生華製藥股份有限公司 filed Critical 東生華製藥股份有限公司
Publication of TW201206437A publication Critical patent/TW201206437A/zh
Application granted granted Critical
Publication of TWI583383B publication Critical patent/TWI583383B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW100115056A 2010-05-03 2011-04-29 治療高血壓之醫藥組成物及方法 TWI583383B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33054010P 2010-05-03 2010-05-03

Publications (2)

Publication Number Publication Date
TW201206437A TW201206437A (en) 2012-02-16
TWI583383B true TWI583383B (zh) 2017-05-21

Family

ID=44903590

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100115056A TWI583383B (zh) 2010-05-03 2011-04-29 治療高血壓之醫藥組成物及方法

Country Status (11)

Country Link
US (2) US20130053411A1 (https=)
EP (1) EP2566478A4 (https=)
JP (1) JP5847162B2 (https=)
KR (1) KR20130061148A (https=)
CN (1) CN102869360B (https=)
AU (1) AU2011250485B2 (https=)
BR (1) BR112012028153A2 (https=)
MY (1) MY161853A (https=)
RU (1) RU2571284C2 (https=)
TW (1) TWI583383B (https=)
WO (1) WO2011137734A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102635B2 (en) * 2013-02-14 2015-08-11 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
WO2017028814A1 (en) * 2015-08-20 2017-02-23 Tsh Biopharm Corporation Ltd. Pharmaceutical composition comprising amlodipine and dextromethorphan
EP4620525A3 (en) 2016-12-14 2025-12-03 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
KR20240096848A (ko) 2017-01-25 2024-06-26 더 조지 인스티튜트 포 글로벌 헬스 고혈압의 치료를 위한 조성물
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097608A2 (en) * 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676177A (en) 1949-11-09 1954-04-20 Hoffmann La Roche Process for the preparation of optically active 3-methoxy-n-methyl morphinans and salts thereof
GB8710493D0 (en) 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
JPH06500554A (ja) * 1990-08-23 1994-01-20 ザ・チルドレンズ・メディカル・センター・コーポレイション エイズ性痴呆、脊髄障害、末梢神経障害、および視覚喪失の治療
JPH04368338A (ja) * 1991-06-12 1992-12-21 Taisho Pharmaceut Co Ltd 鎮咳剤
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5560913A (en) 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
EP1505068A4 (en) * 2002-04-23 2008-03-19 Shionogi & Co PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR100476636B1 (ko) 2002-09-11 2005-03-17 한림제약(주) 엘-(+)-타르트레이트를 이용한 에스-(-)-암로디핀의 제조방법
US7863287B2 (en) * 2002-12-18 2011-01-04 Wyeth Llc Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
US8569374B2 (en) 2004-09-16 2013-10-29 The Trustees Of The University Of Pennsylvania NADPH oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US20060188450A1 (en) * 2005-02-24 2006-08-24 Tim Clarot System and method for suppressing a cough
US7939567B2 (en) * 2006-02-24 2011-05-10 Blue Blood Biotech Corp. Dextromethorphan-based method for treating acne
US7820689B2 (en) * 2006-08-10 2010-10-26 Hua-Lin Wu Methods and compositions for preventing or treating cardiovascular disease
US8569364B2 (en) * 2007-11-28 2013-10-29 Sequoia Pharmaceuticals, Inc. 5-substituted benzofurans as inhibitors of cytochrome P450 2D6

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097608A2 (en) * 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Renin-Angiotensin-Aldosterone System, 2008, vol 9(1), 1-9. *

Also Published As

Publication number Publication date
KR20130061148A (ko) 2013-06-10
TW201206437A (en) 2012-02-16
US20130053411A1 (en) 2013-02-28
CN102869360B (zh) 2015-03-25
EP2566478A1 (en) 2013-03-13
JP5847162B2 (ja) 2016-01-20
US9744165B2 (en) 2017-08-29
MY161853A (en) 2017-05-15
AU2011250485B2 (en) 2016-07-07
AU2011250485A1 (en) 2012-12-06
EP2566478A4 (en) 2014-04-30
BR112012028153A2 (pt) 2018-08-07
CN102869360A (zh) 2013-01-09
WO2011137734A1 (en) 2011-11-10
RU2012151051A (ru) 2014-06-10
US20160235741A1 (en) 2016-08-18
JP2013525460A (ja) 2013-06-20
RU2571284C2 (ru) 2015-12-20

Similar Documents

Publication Publication Date Title
US9744165B2 (en) Method for treating hypertension
EP1096932B1 (en) Antihypertensive combination of valsartan and calcium channel blocker
US6395728B2 (en) Method of treatment and pharmaceutical composition
US6204281B1 (en) Method of treatment and pharmaceutical composition
HUT77315A (hu) Loratadinszármazék allergiás és egyéb betegségek kezelésében való alkalmazásra
AU2009313906A1 (en) Treatment of proteinopathies using a farnesyl transferase inhibitor
TW200838510A (en) A preventive and/or therapeutical agent of hyperlipemia
CN107567444A (zh) 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物
AU2022387121A1 (en) Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
CA2004616A1 (en) Therapeutic use of calcium entry blockers in retinal or optic nerve dysfunction
ES2847904T3 (es) Medicamento para la prevención o el tratamiento de la hipertensión
JP2012532855A (ja) 医薬として使用するための組合せ製剤
US12582648B2 (en) Method for treating central nervous system disorders using dopamine D3 partial agonists
TW201304775A (zh) 使用依普羅沙坦與氨氯地平治療高血壓的組成物和方法
JP5441052B2 (ja) アルツハイマー病治療薬
JPH11335278A (ja) ドフェチリドおよびカルシウムチャネル遮断薬の組合わせ
CN101415425B (zh) 甘油三酯降低剂和高胰岛素血症改善剂
Kondo et al. The discovery of Samsca®(Tolvaptan): the first oral nonpeptide vasopressin receptor antagonist
ITRM20100230A1 (it) Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
MXPA99004460A (en) Combination of dofetilida and a blocking of the calculates
WO2011000564A1 (en) Eltoprazine for the treatment of drug addiction
BRPI0717874A2 (pt) Uso de compostos orgânicos

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees